ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma

European Journal of Cancer

Volumn 50, Issue 10, 2014, Pages 1740-1746

  Laforest, Anais ^a,b   Aparicio, Thomas ^c   Zaanan, Aziz ^a,b   Silva, Fabio Pittella ^a,b   Didelot, Audrey ^a,b   Desbeaux, Aurélien ^a,b   Le Corre, Delphine ^a,b   Benhaim, Leonor ^a,b   Pallier, Karine ^a,b   Aust, Daniela ^e   Pistorius, Steffen ^e   Blons, Hélène ^a,b   Svrcek, Magali ^d   Laurent Puig, Pierre ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

ERBB2; Mutations; Sequencing; Small intestine cancer

Indexed keywords

APC PROTEIN; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; SMAD4 PROTEIN;

ADENOCARCINOMA; ADULT; AGED; APC GENE; ARTICLE; B RAF KINASE GENE; CANCER LOCALIZATION; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DUODENUM; EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; FBXW7 GENE; FEMALE; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE P53; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC PROCEDURES; HUMAN; HUMAN TISSUE; ILEUM; JEJUNUM; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; ONCOGENE K RAS; PIK3CA GENE; PRIORITY JOURNAL; SMAD4 GENE; SMALL BOWEL ADENOCARCINOMA; SMALL INTESTINE CARCINOMA; SOMATIC MUTATION;

ERBB2; MUTATIONS; SEQUENCING; SMALL INTESTINE CANCER;

ADENOCARCINOMA; ADENOMATOUS POLYPOSIS COLI PROTEIN; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHI-SQUARE DISTRIBUTION; DATABASES, GENETIC; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; EUROPE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PHENOTYPE; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84901770070     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.04.007     Document Type: Article

References (17)

1. M.J. Overman, C.Y. Hu, S. Kopetz, J.L. Abbruzzese, R.A. Wolff, and G.J. Chang A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease Ann Surg Oncol 19 5 2012 1439 1445
2. Y. Lu, R. Frobom, and J. Lagergren Incidence patterns of small bowel cancer in a population-based study in Sweden: increase in duodenal adenocarcinoma Cancer Epidemiol 36 3 2012 e158 e163
3. K.Y. Bilimoria, D.J. Bentrem, J.D. Wayne, C.Y. Ko, C.L. Bennett, and M.S. Talamonti Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years Ann Surg 249 1 2009 63 71
4. T. Aparicio, A. Zaanan, M. Svrcek, P. Laurent-Puig, N. Carrere, and S. Manfredi et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment Dig Liver Dis 46 2 2014 97 104
5. M.J. Overman, G.R. Varadhachary, S. Kopetz, R. Adinin, E. Lin, and J.S. Morris et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater J Clin Oncol 27 16 2009 2598 2603
6. A. Zaanan, M. Gauthier, D. Malka, C. Locher, J.M. Gornet, and A. Thirot-Bidault et al. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study Cancer 117 7 2011 1422 1428
7. A. Zaanan, L. Costes, M. Gauthier, D. Malka, C. Locher, and E. Mitry et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study Ann Oncol 21 9 2010 1786 1793
8. T. Aparicio, M. Svrcek, A. Zaanan, E. Beohou, A. Laforest, and P. Afchain et al. Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study Br J Cancer 109 12 2013 3057 3066
9. A.C. Wolff, M.E. Hammond, J.N. Schwartz, K.L. Hagerty, D.C. Allred, and R.J. Cote et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 1 2007 18 43
10. S.A. Forbes, N. Bindal, S. Bamford, C. Cole, C.Y. Kok, and D. Beare et al. COSMIC mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer Nucleic Acids Res 39 Database issue 2011 D945 D950
11. R.K. Kancha, N. von Bubnoff, N. Bartosch, C. Peschel, R.A. Engh, and J. Duyster Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib PLoS One 6 10 2011 e26760
12. R. Bose, S.M. Kavuri, A.C. Searleman, W. Shen, D. Shen, and D.C. Koboldt et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer Cancer Discov 3 2 2013 224 237
13. C.G.A. Network Comprehensive molecular characterization of human colon and rectal cancer Nature 487 7407 2012 330 337
14. C. Kandoth, N. Schultz, A.D. Cherniack, R. Akbani, Y. Liu, and H. Shen et al. Integrated genomic characterization of endometrial carcinoma Nature 497 7447 2013 67 73
15. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A.A. Margolin, and S. Kim et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 7391 2012 603 607
16. M. Tanner, M. Hollmen, T.T. Junttila, A.I. Kapanen, S. Tommola, and Y. Soini et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann Oncol 16 2 2005 273 278
17. Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, and A. Sawaki et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 9742 2010 687 697